Company / Shareholders' Equity
Denali Therapeutics Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.0B
FY2025
5-year range
$394.9M / $1.2B
FY2021-FY2025
Trend
-17.6%
vs FY2024
Sector context
#48 of 213
Health Care
What the data says
Denali Therapeutics Inc.'s shareholders' equity of $1.0B is higher than 77% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from -$94M in FY2018 to $1.2B in FY2024.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of +13.1%. Top quartile in the Health Care sector.
Remained stable around $1.0B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -4.1%
- 5-Year CAGR
- +13.1%
- 10-Year CAGR
- -
Sector benchmark
-60.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.1%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 17.6% year-over-year.
- Ranks #48 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | -17.6% |
| FY2024 | $1.2B | +19.3% |
| FY2023 | $1.0B | -10.4% |
| FY2022 | $1.2B | +191.4% |
| FY2021 | $394.9M | -27.8% |
| FY2020 | $546.8M | +17.4% |
| FY2019 | $465.8M | +594.7% |
| FY2018 | -$94.2M | -120.2% |
| FY2017 | $465.8M | +594.7% |
| FY2016 | -$94.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026